{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:10:22Z","timestamp":1758046222103,"version":"3.44.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.ando.2012.10.002","type":"journal-article","created":{"date-parts":[[2013,1,18]],"date-time":"2013-01-18T12:18:45Z","timestamp":1358511525000},"page":"49-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient"],"prefix":"10.1016","volume":"74","author":[{"given":"Salha","family":"Fendri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pelin","family":"Karaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyne","family":"Tiev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Buchfelder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Daniel","family":"Lalau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2012.10.002_bib0005","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1210\/endo.140.8.7047","article-title":"The human growth hormone antagonist B2036 does not interact with the prolactin receptor","volume":"140","author":"Goffin","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.ando.2012.10.002_bib0010","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1126\/science.256.5064.1677","article-title":"Rational design of potent antagonists to the human growth hormone receptor","volume":"256","author":"Fuh","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.ando.2012.10.002_bib0015","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1210\/jc.2009-2670","article-title":"Acromegaly Consensus Group (2009)","volume":"95","author":"Giustina","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.10.002_bib0020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1530\/EJE-08-0843","article-title":"Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5years (median 2.2years) of follow-up in 86\u00a0patients","volume":"160","author":"Neggers","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2012.10.002_bib0025","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(05)63011-5","article-title":"Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly","volume":"365","author":"Feenstra","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2012.10.002_bib0030","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1210\/jc.2005-0531","article-title":"Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist","volume":"90","author":"Jorgensen","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.10.002_bib0035","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1530\/EJE-09-0322","article-title":"ACROSTUDY: the first 5years","volume":"161","author":"Trainer","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2012.10.002_bib0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1530\/EJE-08-0910","article-title":"Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MRI re-evaluations of the German Pegvisomant Observational Study","volume":"161","author":"Buchfelder","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2012.10.002_bib0045","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0169-409X(03)00111-X","article-title":"Pegvisomant in the treatment of acromegaly","volume":"55","author":"Parkinson","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ando.2012.10.002_bib0050","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1530\/EJE-09-0333","article-title":"Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY","volume":"161","author":"Brue","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2012.10.002_bib0055","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.1.02112","article-title":"Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-1 levels, tumor mass, hypertension and glucose tolerance","volume":"154","author":"Colao","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2012.10.002_bib0060","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1530\/EJE-08-0205","article-title":"Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials","volume":"159","author":"Jimenez","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2012.10.002_bib0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1530\/EJE-08-0705","article-title":"Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy","volume":"160","author":"Marazuela","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2012.10.002_bib0070","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2005-0311","article-title":"Outcome of gamma knife radiosurgery in 82\u00a0patients with acromegaly: correlation with initial hypersecretion","volume":"90","author":"Castinetti","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ando.2012.10.002_bib0075","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1210\/jc.2002-021663","article-title":"Gamma-knife radiosurgery in acromegaly","volume":"88","author":"Attanasio","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.10.002_bib0080","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1210\/jc.2009-1239","article-title":"Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study","volume":"95","author":"Buhk","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.10.002_bib0085","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ghir.2011.03.004","article-title":"Combination treatment with somatostatin analogues and pegvisomant in acromegaly","volume":"21","author":"Neggers","year":"2011","journal-title":"Growth Horm IGF Res"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426612011912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426612011912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:45:42Z","timestamp":1757717142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426612011912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0003426612011912"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2012.10.002","relation":{},"ISSN":["0003-4266"],"issn-type":[{"type":"print","value":"0003-4266"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2012.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}